ABSTRACT The larvae of calliphorid ßies are used to debride wounds of patients with severe tissue destruction, often concurrently with antimicrobials. The current study evaluates the effects of ceftazidime, tobramycin, amikacin, gentamicin, polymyxin B, doxycycline, paromomycin, amphotericin B, sodium stibogluconate, and miltefosine at 1, 10, and 100ϫ the Maximum Clinical Concentration (mg/kg/d) in raw liver assays. Effects on larvae were small and depended on dose and antimicrobial formulation, with hours in assay (24 or 48 h) having a signiÞcant effect on larval survival. Sodium stibgluconate had the strongest effect on maggot survival (80.0% at 48 h). These results suggest that the antimicrobials tested here may be used simultaneously with maggot debridement therapy, and may actually increase the effectiveness of maggot debridement therapy in certain applications where Ͼ1 ϫ Maximum Clinical Concentration is indicated, such as topical creams for cutaneous leishmaniasis.
The use and popularity of maggot debridement therapyÑthe treatment of wounds with live ßy larvae (hereafter MDT)Ñis increasing in many countries throughout the world (Sherman et al. 2000) . Maggot debridement therapy is used as a treatment for serious and recalcitrant wounds, including life-and limbthreatening infections after unsuccessful antibiotic treatments. Maggot debridement therapy is now used as an adjunct to conventional modalities, and may be administered to patients concurrently receiving systemic antibiotics (Teich and Myers 1986, Jukema et al. 2002) . In addition to bacterial soft-tissue infections, cutaneous leishmaniasis may also be treated simultaneously by chemotherapy and by maggot debridement therapy. Leishmaniasis is one of the most common tropical dermatoses worldwide and is of major public health importance (Ameen 2010) . Maggot therapy may be a useful adjunct to conventional cutaneous leishmaniasis treatment protocols, but the response of maggots to typical antileishmania compounds has not been tested. In both cases, the chemotherapy may prevent effective maggot debridement therapy if the chemicals are toxic, directly or indirectly, to the maggots.
Bacteria play a crucial role in maggot development for some ßy species, but less so for others (Ahmad et al. 2006) . House ßy larval development is greatly enhanced by the presence of selected bacterial strains (Zurek et al. 2000) . However, the presence of bacteria may have a detrimental effect on the growth and survival of blow ßies, such as the secondary screwworm, Cochliomyia macellaria (F.) (Diptera: Calliphoridae) (Ahmad et al. 2006) . The larval secretions of calliphorid ßies, especially Lucilia sericata (Meigen) (Diptera: Calliphordidae), have strong antibacterial properties (BexÞeld et al. 2004) , and their adaptive signiÞcance may be to increase growth by suppressing pathogenic microbes on the food substrate (Sherman et al. 2000) .
With the revival of maggot therapy as a viable adjunct to conventional modalities, clinicians are Þnding that simultaneous administration of antimicrobials during a course of maggot therapy is useful for patients with infections that showed no response to the classical approach of surgical wound debridement and antimicrobial therapy (Jukema et al. 2002) . While there are no in vivo studies, maggot excretions/secretions increase the potency of selected antimicrobials in a dose-dependent fashion for in vitro assays (Cazander et al. 2010a ). Thus, it is possible that antimicrobials may impact medical maggot survival during treatment either by acting on the maggots directly, or by acting on bacteria that then interact with the maggots. One previous in vitro study found that only very high doses (Ͼ100ϫ recommended dose) of antimiDisclaimer: The following material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as ofÞcial, or as reßecting true views of the Department of the Army or the Department of Defense.
1 Corresponding author, e-mail: george.peck@amedd.army.mil. crobials impacted maggot growth and development (Sherman et al. 1995) . We evaluated the effects of various classes of antimicrobials commonly used to treat bacterial, fungal, and protozoal infections in human skin and soft tissue, including cephalosporins (ceftazidime), aminoglycosides (tobramycin, amikacin, and gentamicin), polymyxins (polymyxin B), tetracyclines (doxycycline), an antifungal (amphotericin B), and antileishmanials (paromomycin, sodium stibogluconate, and miltefosine) on L. sericata larvae.
Methods and Materials
L. sericata larvae came from a colony started from Þeld collections in Silver Spring, MD, in 2010. Flies were reared using previously published methods with slight modiÞcations (Sherman and Wyle 1996) . Adult rearing modiÞcations included in BugDorm cages (BioQuip, Rancho Dominguez, CA; 0.03 m 3 ), and feeding them Muscle Milk (CytoSport, Benicia, CA) as a protein source. Egg collection modiÞcations included placing freshly thawed food grade bovine liver (50 g) on a small square of aluminum foil for an egg laying substrate. Fecundity was similar to that reported in Sherman and Wyle (1996) . Maggot rearing modiÞcations included using washed sand in place of sawdust in rearing buckets, and placing ßy eggs onto freshly thawed liver and small paper towel in aluminum foil ÔboatsÕ made with a 300 cm 2 piece of foil in tear-drop shape. All assays were conducted in a temperature (22 Ϯ 2ЊC) and humidity (50 Ϯ 2% RH) controlled insectary at Walter Reed Army Institute of Research. While conducting assays nearer to body temperature may approximate the clinical situation more closely, we saw no difference in survival at 35ЊC for four replicate assays for deoxycycline (compared with 22ЊC at 10ϫ; t ϭ 1.22, df ϭ 6, P Ͼ 0.2), and previous work (Sherman et al. 1995 ) used a temperature (25ЊC) similar to our standard insectary temperature range. Assays consisted of 0.4 g chunks of freshly thawed food-grade beef liver, placed into lidless small petri dishes (Fisherbrand Media-miser, 35 ϫ 10 mm; Fisher ScientiÞc, Rockville, MD), the total amount of liver per dish being 2.0 g. These small dishes were then placed inside large petri dishes (VWR, Corning culture dishes, 150 ϫ 25 mm, Radnor, PA) to allow maggot movement and air circulation. The necessary quantity of reagent grade ceftazidime, tobramycin, polymyxin B, amikacin, doxycycline, gentamicin, and miltefosine (Sigma-Aldrich, St. Louis, MO), paromomycin and amphotericin B (Fisher ScientiÞc), and stibogluconate (VWR) was diluted with ddH 2 O to make Þnal antimicrobial concentrations in liver plate assays approximating 1, 10, and 100ϫ Maximum Clinical Concentration (milligrams antimicrobial/kilograms body weight/day, hereafter MCC; Grayson 2010). Antimicrobial solutions (1 ml) were pipetted directly onto the liver chunks (total volume of liver and MCC solution was 3 ml), soaking them completely and creating a moat of solution surrounding the bolus of liver within the plate. The moat lasted a few hours, being replaced by a liver-antimicrobial puree as maggots tunneled through/digested/churned the liver chunks, dissolving them and resulting in a homogeneous slurry by 24 h. Because wounds are not sterile environments, eggs were not sterilized and maggots were not reared on sterile media before placement onto the liver bolus (10 per plate). Plates within treatments were replicated 4ϫ, and separate assays were conducted for each treatment on three separate calendar days. Control plates received liver and ddH 2 O only.
L. sericata eggs were collected by presenting small chunks of freshly thawed beef liver on foil into adult cages. Eggs were deposited within 4 h and placed on a 20 g slice of freshly thawed liver for hatching at 22ЊC and subsequent incubation for 48 h. On the day of the assay, 10 48-h-old L. sericata larvae (small second instars) were added to each assay plate (controls and treatments) and incubated in semidarkness at 22ЊC for 48 h. Maggots were examined for survival at 24 and 48 h. Ataxic maggots were considered dead. Each MCC was evaluated on at least three separate calendar day assays, for a total of n Ն120 maggots per MCCantimicrobial pair. Mean control survival Ͻ85% for a given assay run was criteria for exclusion of assay data from analysis. To make comparisons across time within treatments and MCC classes, and to gauge treatment effect size, we calculated ratios of mean treatment percent survival (numerator) and mean control percent survival (denominator), and their corresponding 95% CIs (Feuerstein et al. 1997) . Factorial analysis of variance (ANOVA) on arcsine-transformed proportion of larvae surviving was performed on the R statistical platform (version 2.14.0; The R Foundation for Statistical Computing, http://www.r-project.org/). We conducted tests of independence (log-likelihood ratio [G-statistic] with WilliamÕs correction) for 2 ϫ 2 contingency tables (Sokal and Rohlf 1995) in Excel. For tables found to be signiÞcant (P Ͻ 0.05), we used logistic regression in R to determine 95% CIs for odds ratios.
Results
Larvae that fed on the control had an overall survival rate of 91.5 Ϯ 0.3% (mean Ϯ SE; n ϭ 60), while the larvae that fed on the antimicrobial treatments had an overall survival rate of 92.8 Ϯ 0.5% (Table 1) . Three-way ANOVA (Factor 1, antimicrobial; Factor 2, dose; Factor 3, time) of larval proportion surviving showed a signiÞcant main effect of time (24 h vs. 48 h) on larval survival (F ϭ 6.47; df ϭ 1; P ϭ 0.012), but no other signiÞcant main effects or interactions (␣ ϭ 0.05). Percent treatment survival was compared with percent control survival as a ratio (Feuerstein et al. 1997) for each antimicrobial-MCC-time combination (60 total; Fig. 1 ). This analysis yielded an overall ratio of 1.01 Ϯ 0.01(mean Ϯ SE; n ϭ 60), with within-MCC concentration ratios of 0.98 Ϯ 0.004 (mean Ϯ SE, n ϭ 20; 1ϫ), 1.01 Ϯ 0.001 (10ϫ), and 1.03 Ϯ 0.001(100ϫ).
To test the null hypothesis that maggot survival was independent of treatment type (antimicrobial vs. con-trol), we ran 60 tests of independence for each antimicrobial-MCC pair at 24 or 48 h using two-way tables. Of the 60 two-way tables analyzed, 13 were signiÞcant (P Ͻ 0.05; Table 2 ) with 10 tests showing a positive impact on maggot survival (ratio Ͼ1.00) and three tests showing a negative impact on maggot survival (ratio Ͻ1.00). For 1ϫ MCC at 24 h, survival in only one antimicrobial treatment was signiÞcantly different from control survival and had a negative effect: maggots reared in control liver were 3.54ϫ (odds ratio 95% CI, 1.25Ð10.0; Log likelihood statistic with Williams correction [G] ϭ 6.46, df ϭ 1, P Ͻ 0.05) more likely than maggots reared in polymyxin B-treated liver to survive. For 1ϫ MCC at 48 h, survival in two antimicrobial treatments were signiÞcantly different from control survival with mixed effect: maggots reared in ceftazidime-treated liver were 3.55ϫ (positive effect, 95% CI: 0.95Ð13.22, G ϭ 4.04, df ϭ 1, P Ͻ 0.05) more likely than maggots reared in control liver to survive, and maggots reared in control liver were 2.52ϫ (negative effect, 95% CI: 1.16 Ð5.48, G ϭ 5.76, df ϭ 1, P Ͻ 0.05) more likely to survive compared with maggots reared in paromomycin-treated liver. For 10ϫ MCC assays at 24 h and 48 h, results were mixed. Survival in two antimicrobial treatments were signiÞcantly greater than control survival: maggots reared in tobramycin-treated liver for 24 and 48 h, respectively, were 3.45ϫ (95% CI: 1.1Ð10.8, G ϭ 5.13, df ϭ 1, P Ͻ 0.05) and 3.69ϫ (95% CI: 1.3Ð10.2, G ϭ 7.23, df ϭ 1, P Ͻ 0.05) more likely than maggots reared in control liver to survive, while maggots reared in deoxycyclinetreated liver for 24 and 48 h were 9.15ϫ (95% CI: 1.1Ð72.6, G ϭ 7.16, df ϭ 1, P Ͻ 0.05; identical results for both times) more likely than maggots reared in control liver to survive. However, survival in one antimicrobial treatment (10ϫ MCC at 24 and 48 h), was significantly less than control survival: maggots reared in control liver were 2.25ϫ (95% CI: 1.1Ð 4.7, G ϭ 4.72, df ϭ 1, P Ͻ 0.05) more likely to survive than maggots reared in liver treated with sodium stibgluconate. For 100ϫ MCC at 24 h, survival in two antimicrobial treatments were signiÞcantly different from control survival with positive effect: maggots reared in tobramycin-treated liver were 4.36ϫ (95% CI: 1.0 Ð20.0, G ϭ 4.55, df ϭ 1, P Ͻ 0.05) more likely than maggots reared in control liver to survive, while maggots reared in miltefosine-treated liver were 4.59ϫ (95% CI: 1.02Ð 20.73, G ϭ 5.22, df ϭ 1, P Ͻ 0.05) more likely than maggots reared in control liver to survive. For 100ϫ MCC at 48 h, survival in three antimicrobial treat- Grayson (2010) . b n Ն 120, 10 maggots per plate ϫ 4 plates ϫ at least three separate assay dates; SE for means of three assay dates; 24 and 48 h repeated measure on same replicates. Assay runs with control survival Յ85% were excluded from analysis.
c Mean percent control survival of all assays used within a given MCC analysis.
ments were signiÞcantly different from control survival with positive effect: maggots reared in ceftazidime-and tobramycin-treated liver were 3.91ϫ (95% CI: 1.29 Ð11.81, G ϭ 7.17, df ϭ 1, P Ͻ 0.05) more likely than maggots reared in control liver to survive, while maggots reared in amikacin-treated liver were 3.10ϫ (95% CI: 1.12Ð 8.56), G ϭ 5.50, df ϭ 1, P Ͻ 0.05) more likely than maggots reared in control liver to survive.
Discussion
Larval survivalÑand thus the utility of maggot debridement therapyÑwas not affected by therapeutic doses of the antimicrobials examined here. The close match between overall survival rate between treatment and controls and the overall and speciÞc ratios of treatment-control near unity suggests that larvae tolerate clinical maximum doses of the 10 antimicrobials examined here in vitro, and that they will most likely tolerate the same antimicrobials and doses in vivo. We made no adjustment for inactivation of antimicrobials because of enzymatic decomposition from larval secretions, protein binding, or tissue penetration. However, for most of these antimicrobials, the in vivo tissue concentrations are expected to be less than the concentrations larvae experienced by direct pipetting of solutions onto liver in the assay plates used here. The antimicrobial tolerances exhibited by L. sericata larvae in the current study have broad implications. To our knowledge, this is the Þrst time in vitro evidence is presented showing medical maggots are able to survive high doses of antimicrobials that target gram-positive organisms and Pseudomonas aeruginosa Migula (ceftazidime, tobramycin, polymyxin B, amikacin, and doxycycline), an antifungal (amphotericin B), and antileishmanials (sodium stibgluconate, paromomycin, and miltefosine).
The results of our larval-antimicrobial assays are comparable to an earlier study by Sherman et al. (1995) . Whereas Sherman showed that gentamicin Fig. 1 . Effect size as ratio of (treatment percent survival/control percent survival) for antimicrobials at 1ϫ (A), 10ϫ (B), and 100ϫ (C) MCC. Error bars are 95% CI for ratios (n Ն 3).
had the strongest (and only signiÞcant) treatment effect at 1,000ϫ, other antimicrobial formulations gave mixed survival results similar to ours. While our study did not follow larvae through all developmental stages, we added multiple calendar day replicates to increase the robustness of experimental inferences made. We focused on survival during the window of time when larvae are used in clinical application for wound debridement, rather than survival of stages in time periods far removed from the maggot debridement therapy treatment interval. While data on larval feeding and weight gain would inform studies focused on debridement effectiveness, this study focused on differences in larval survival because of antimicrobial treatment. We observed no differences in larval size for all treatments at all concentrations on all assay dates; larvae were generally a strong second instar at 24 h and a robust third instar at 48 h, including when treatments were compared with controls. The current study reveals speciÞc details about the small differences between treatment survival and control survival across antimicrobial formulations and time, and supports data trends and the general conclusions made by Sherman et al. (1995) .
Because larval food-associated bacteria play a signiÞcant role on larval development of many ßies (Zurek et al. 2000) , we expected the antimicrobials within the plate assay environment to inßuence the survival of larvae in this study. Altering the microbial environment of ßy larvae can impact their development (Amato et al. 1980) , and food-associated bacteria play a critical role in the larval growth of the house ßy (Musca domestica L.), the stable ßy (Stomoxys calcitrans (L.)), the face ßy (Musca autumnalis (De Geer)), and the horn ßy (Haematobia irritans (L.)) (Moon 2002) . In contrast, the secondary screwworm (Cochliomyia macellaria F.) required no bacteria to complete larval development, and was negatively impacted by the presence of Providencia spp. and Escherichia coli O157:H7 (Ahmad et al. 2006) . However, there are no deÞnitive studies showing that bacteria are required for larval development of L. sericata. Interestingly, some species of bacteria and bacterial assemblages are particularly harmful to ßies. Drosophilia melanogaster Meigen larval survival is signiÞ-cantly reduced by oral inoculation with cultures of Pseudomonas entomophila (Vodovar et al. 2005) , and adult D. melanogaster survival is strongly impacted by oral inoculation with human oropharyngeal community samples spiked with Pseudomonas aeruginosa (Sibley et al. 2008 ). Indeed, certain P. aeruginosa strains have a strong impact on L. sericata survival in blood plate assays (Andersen et al. 2010 ). However, a study using slants of liquid media found that L. sericata larvae were able to tolerate high levels of pathogenic bacteria for 16 h (Cazander et al. 2009a ). Thus, bacterial challenge in wounds may not be the primary factor determining larval mortality. For example, maggots applied to the wounds of patients with pyoderma gangrenosum have experienced high mortality due, at least in part, to the combined effect of immunosuppressant chemotherapy and toxic TNF-␣ cytokine levels within the wound matrix (Renner et al. 2008) . Other than the one Pseudomonas-larval KaplanÐMeier analysis by Andersen et al. (2010) , there are no studies focused on the effect of bacterial strain and bacterial dose on L. sericata larval survival. More solid medium assays for assessing the effect of bacterial challenge on L. sericata larval survival in vitro, especially on the effect of speciÞc bacterial strains and mixtures of bacterial strains are needed.
To cope with the microbial milieu in their natural environments, many ßy maggots have evolved traits that allow normal growth in diverse assemblages of microbes (Catts and Mullen 2002) . One trait of interest to wound healing research is the expression of chemicals that inhibit or protect maggots from potential pathogens. For example, L. sericata maggot excretions and secretions in liquid culture assays (LCAs) may show strong antimicrobial properties (BexÞeld et al. 2004 , Jaklic et al. 2008 ) and strong antibioÞlm properties (Cazander et al. 2009b (Cazander et al. , 2010b van der Plas et al. 2008) . However, the results of excretions and secretions studies do not always show a strong antimicrobial effect for LCAs (Barnes et al. 2010) , and some LCAs show increased bacterial growth in the presence of L. sericata maggots (Cazander et al. 2009a) . Internal microbial ecology studies show that bacteria such as E. coli do not survive passage through the L. sericata larval gut (Daeschlein et al. 2007 , Mumcuoglu et al. 2001 . Larvae can also inßuence the density and diversity of microbes in their local environment. Jaklic et al. (2008) examined changes in 33 separate wound microbiomes before and after application of medical maggots. They found that maggots decreased bacterial density (as number of isolates) and diversity (as number of strains), and completely cleared all pathogenic bacteria from 76.6% of wounds treated. While sterile assays provide controlled environments that allow unambiguous isolation of treatment effects (Zurek et al. 2000) , the raw liver assays described here more closely resemble the natural microbiome that may be present in real-world wounds. Our experimental design did not include assays with a representative mix of pathogens found in wounds (Dowd et al. 2008 (Dowd et al. , 2010 , however, food-grade liver has its own assemblage of microorganisms, and some of them constitute pathogens in human wounds (Bohaychuk et al. 2006) . Our high control survival (18 of 23 assay calendar days had control survival Ͼ85%) suggests that ßy-speciÞc pathogens were most likely absent from, or in small densities in, our plate assay environments. Chemical control of bottle ßies (Calliphoridae, to include L. sericata) is common in agricultural settings (Catts and Mullen 2002) . Tolerance to xenobiotics is an emerging, artiÞcially selected trait in ßy families closely related to L. sericata (Drummond et al. 1988) , especially where ßies have had time to develop resistance across generations (Keiding 1999) . Larvae of L. sericata have previously shown susceptibility to high concentrations of 8 inorganic and 30 organic chemicals in ground meat feeding assays (Knipling 1941) . Upon comparison, there were Þve instances where our antimicrobial concentrations overlapped the range of lethal chemical concentrations (1Ð5 ppt) in Knipling (1941) : at 10ϫ MCC for ceftazidime (1 ppt), and at 100ϫ MCC for ceftazidime (10 ppt), amikacin (1.2 ppt), paromomycin (1.1 ppt), and stibgluconate (2.0 ppt). This tolerance is not surprising because antimicrobials act on targets not present in eukaryotic organisms (Grayson 2010) .
Leishmaniasis has been and continues to be a severe public health problem (Desjeux 2004) . The therapeutic arsenal against cutaneous leishmaniasis is very limited. Pentavalent antimonial compounds have been the drugs of choice for treatment of cutaneous leishmaniasis for over 50 yr (Croft and Olliaro 2011) . Despite their record of successful clinical application, these drugs require daily injections, have many side effects including prolonged healing time (Almeida and Santos 2011), and may be losing their effectiveness because of resistance (AṏtÐOudhia et al. 2011) . While treatment alternatives exist, such as miltefosine (Sindermann et al. 2004) , new therapeutic modalities are needed. For example, without aid of chemical therapeutics, maggots of L. sericata increased healing time in a hamster model of cutaneous leshmaniasis (Arrivillaga et al. 2008) . Thus, MDT, combined with the antileishmanials tested in the current study, offer a combinatorial therapy that may be highly effective.
Combinatorial therapeutics is an emerging modality of treatment for traumatic wound care. The medical maggot (L. sericata), an FDA-approved medical device, has been studied for its ability to tolerate clinical relevant doses of various antibiotics to support the extant practice of simultaneous use of MDT with systemic antibiotics in an integrated approach to wound care. Multi-drug resistant organisms, invasive fungal pathogens, and resistant strains of Leishmania continue to challenge clinicians in a diversity of care settings. Because traditional treatment regimes may lack sufÞcient complexity to deal with all aspects of the wound healing process, there is a clear and continuing need for development and testing of innovative traumatic and chronic wound treatment approaches. The results presented here offer an expanded view of biocompatibility in treatments using MDT simultaneously with relevant classes of antimicrobials for a broad variety of wound types.
